Takeda Pharmaceutical Company Limited

Takeda Chemical Industries, Inc.

Naoki Miyamoto

Shinichi Imamura

Takaharu Hirayama

Nozomu Sakai

Yasushi Hattori

Tatsuki Koike

Tsuneo Oda

Takahiro Sugimoto

Yasutaka Hoashi

Norihito Tokunaga

Yuichi Kajita

Yoshiteru Ito

Keisuke Imamura

Yuhei Miyanohana

Tohru Miyazaki

Koichiro Fukuda

Kohei Takeuchi

Rei Okamoto

Yoshito Terao

Yasuhisa Kohara

Taiichi Ohra

Dilhumar Uyghur

Masanori Kawasaki

Masaki Seto

Mitsuru Shiraishi

Masanori Baba

Naoyuki Kanzaki

Shigemitsu Matsumoto

Yoshio Aramaki

Yuji Iizawa

Shumpei Murata

Shinichi Masada

Tadashi Umemoto

Jun Chiba

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

Heterocyclic compound

Provided is an oligonucleic acid analog which contains, as at least one structural unit thereof, a modified nucleic acid monomer compound which is a ring-open nucleoside having a cleaved carbon-carbon bond between the 2' and 3&#x2032; positions and a substituent hydroxymethyl group at the 4&#x2032; position. When used as siRNA, the oligonucleic acid analog exhibits superior biological stability and target gene expression inhibiting activity. The oligonucleic acid analog can be used in antisense methods, ribozyme methods, and decoy methods, etc., can be used as a nucleic acid aptamer, and can also be used as a nucleic acid probe or molecular beacon, etc., or in genetic diagnostics, etc.

Modified nucleic acid

The present invention provides a fused heterocyclic derivative having a strong kinase inhibitory activity and use thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

Fused heterocyclic derivatives and use thereof

The present invention provides a fused heterocyclic derivative having a potent kinase inhibitory activity and use thereof. A compound represented by the formula (I): wherein each symbol is as defined in the specification, except a particular compound, or a salt thereof, and a pharmaceutical agent containing the compound or a prodrug thereof, which is a kinase (VEGFR, VEGFR2, PDGFR, Raf) inhibitor, an angiogenesis inhibitor, an agent for the prophylaxis or treatment of cancer, a cancer growth inhibitor or a cancer metastasis suppressor.

Imidazo-pyridazinyl compounds and uses thereof

Fused heterocyclic derivative and use thereof

The present invention provides an imidazopyridazine derivative compound having a potent kinase inhibitory activity and a pharmaceutical agent thereof useful for treatment or prevention of cancer and the like. One such compound is represented by the formula: or a salt thereof or a prodrug thereof. The pharmaceutical agent contains the imidazopyridazine derivative compound or a prodrug thereof, which is a kinase (VEGFR, VEGFR2, PDGFR, Raf) inhibitor, an angiogenesis inhibitor, an agent for the prophylaxis or treatment of cancer, a cancer growth inhibitor, or a cancer metastasis suppressor.

Imidazopyridazine derivative having kinase inhibitory activity and pharmaceutical agent thereof

The present invention provides a novel benzazepine derivative represented by formula: wherein, Ris a 5- or 6-membered aromatic ring, Ris lower alkyl group, etc., Y is an optionally substituted imino group, ring A and ring B are independently an optionally substituted aromatic ring, W is formula &#x2014;W&#x2014;X&#x2014;W&#x2014; (Wand Ware independently S(O)(m1 is 0, 1, or 2), etc., and Xis an optionally substituted alkylene group etc.), a preparation method and use thereof.

Benzazepine derivative, process for producing the same, and use

Growing community of inventors

Tsukuba, Japan

Naoki Miyamoto